Uroplakin II Expression in Breast Carcinomas Showing Apocrine Differentiation: Putting Some Emphasis on Invasive Pleomorphic Lobular Carcinoma as a Potential Mimic of Urothelial Carcinoma at Metastatic Sites

Figure 2

Immunohistochemical findings. (a) IPLC case 3: immunopositivity for uroplakin II (score 3+) (×400). (b) cILC case 4: immunonegativity for uroplakin II (score 0) (×400). (c) AC case 4: immunopositivity for uroplakin II (score 2+) (×400). (d) AM case 3: immunopositivity for uroplakin II (score 3+). Note immunonegativity for normal breast epithelium (×400). (e) IPLC case 5: immunopositivity for GATA3 (score 3+) (×400). (f) cILC case 3: immunopositivity for GATA3 (score 3+) (×400). (g) AC case 8: immunopositivity for GATA3 (score 1+) (×400). (h) AM case 4: immunonegativity for GATA3 (score 0). Note immunopositivity for normal breast epithelium (×400). (i) IPLC case 3: scattered immunopositive tumor cells for p63 (×400). (j) IPLC case 3: scattered immunopositive tumor cells for p40 (×400). IPLC: invasive pleomorphic lobular carcinoma; cILC: classic invasive lobular carcinoma; AC: apocrine carcinoma; AM: apocrine metaplasia.

(a)  

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)